Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
      • Real World Data
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Lonza

Evaluate

Thumbnail
January 17, 2023

Biopharma's stock market winners of 2022 revealed

Pipeline performers including Lilly, Daiichi and Sarepta topped the stock market gainers last year, as the Covid trade was thoroughly unwound.

Thumbnail
January 21, 2021

Biopharma’s stock market winners and losers in 2020

Article image
Vantage logo
May 21, 2020

Astrazeneca moves to upstage Moderna in Covid-19 vaccines

The UK big pharma group unveils funding and a clinical programme that could overshadow the efforts of its biotech rival.

Article image
Vantage logo
May 01, 2020

Lonza to do the heavy lifting for Moderna’s Covid-19 vaccine

Moderna becomes the latest coronavirus vaccine player to act on the need for a major manufacturing push.

Article image
Vantage logo
May 17, 2019

Upcoming events – Phase III data for Chiasma and Novartis

Chiasma hopes to be able to file its oral acromegaly therapy by year-end, and Novartis wants to shore up its MS franchise.

Article image
Vantage logo
April 16, 2019

Catalent puts down a bet on the future of gene therapy

Article image
Vantage logo
June 25, 2018

The $100,000 problem gene therapy companies would rather not mention

The high doses of recently studied gene therapies threaten manufacturing problems that few have fully considered.

Vantage logo
January 17, 2017

M&A in 2016: Pause for breath in a shifting market

Vantage logo
July 04, 2016

Lion the first beneficiary of NCI’s trial resumption

Vantage logo
August 24, 2015

TiGenix plugs gap with EU data

Vantage logo
March 18, 2010

Teva triumphs in 'must-win' battle for Ratiopharm

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up